ClinicalTrials.gg
CompletedNCT04068272BOSRETUpdated Feb 16, 2023

Safety of Bosentan in Type II Diabetic Patients

A Phase 1 interventional study of Bosentan and Placebo in Diabetes Mellitus, sponsored by Retinset SL. Completed at 2 sites in Spain. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-02-16.

Sponsored by Retinset SL · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 254 studies in Diabetes Mellitus with a site in Spain — 20 open to participants now, 29 under way, 5 of them phase 3. Diabetes Mellitus · Spain.

Enrollment
200th of 211
22 · median 394
Started
2019
with 6 others
Phase 1
2 of 254
none open now
Registered
186th of 254
by date

Among the 254 studies in Diabetes Mellitus with a site in Spain, this one is the 200th largest by enrollment of the 211 interventional ones that give a count, is one of 7 that started in 2019, is one of 2 in phase 1, and was the 186th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

20 of the 254 studies in Diabetes Mellitus with a site in Spain are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 254 studies in Diabetes Mellitus with a site in Spain, or all of them as a file.
02

Study summary

This study evaluates the safety of topical Bosentan in Type II Diabetes patients

Read the detailed description

The study is a Phase I, masked, placebo controlled clinical trial to assess safety of topical Bosentan in Type II Diabetes patients with no diabetes retinopathy

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

Keywords

  • Diabetes
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed ;
  • Type II Diabetes Mellitus;
  • 18 or more years old

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding Women
  • Known allergy or intolerance to product or any of its
  • Severe corneal abnormalities
  • Any relevant ocular / ophthalmic pathology that may put study results at risk in the opinion of Principal Investigator
  • Any sign or symptom of Diabetes Retinopathy
  • Any ocular surgery in the 6 previous months to study inclusion
  • Uncontrolled diabetes in the previous 3 months to inclusion or levels ≥ 9% at baseline.
  • Oxford Scale or OSDI scores compatible with study failure at inclusion visit. (Oxford ≥ 5 or OSTDI ≥ 13)
  • Previous hepatopathy history or signs of hepatopathy at baseline.
  • Contact lens use
  • Actual treatment with the commercially available presentation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Treatment

    The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized

    Drug: Bosentan

  • Placebo comparator
    Placebo

    The patient will receive investigational product in one eye and placebo in the other eye. The allocation of treatment / placebo is masked and randomized

    Drug: Placebo

Interventions

  • Eyedrop

  • DrugPlacebo

    Ophthalmic eyedrop with the exact same excipient of the drug arm without the active compound

06

What researchers measure

Primary outcomes

  1. Epitheliopathy

    Presence of epitheliopathy in the cornea or conjunctiva

    Time frame: 1 month

Secondary outcomes

  1. Presence of ocular discomfort

    Presence of ocular discomfort assessed with Ocular Surface Disease Index (OSDI) questionnaire

    Time frame: 1 month

  2. Anterior segment inflammation

    Presence of any sign of clinically significant inflammation at anterior segment

    Time frame: 1 month

07

Study locations

2 sites
  • Hospital Universitario de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • IOBA
    Valladolid, 47011, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in May 2022, 32 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 32 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2019
First posted
Aug 28, 2019
StartActual
Sep 7, 2019
Primary completionActual
May 20, 2022
CompletionActual
May 20, 2022
Last update
Feb 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04068272
Lead sponsor
Retinset SL
Collaborators
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Sep 7, 2019
Primary completion
May 20, 2022
Completion
May 20, 2022
Last update
Feb 16, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bosentan

Start the discussion